Discovery Teal HRP chromogen detection kit, 3/18
March 2018—Roche launched the Discovery Teal HRP kit, a modular-based detection kit to identify and profile biomarkers and cell populations in tissue-based research.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
WHO awards prequalification to Aptima assay, 3/18
March 2018—Hologic announced that its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization prequalification for in vitro diagnostics.
Inova launches next-gen EIA/IFA processor, 3/18
March 2018—Inova Diagnostics announced the launch of its Quanta-Lyser 3000, a fully automated enzyme-linked immunoassay and immunofluorescence assay processor for use in clinical laboratories.
cfDNA reference standard for EGFR mutations, 3/18
March 2018—Horizon Discovery launched its EGFR Multiplex cfDNA Reference Standard. The cell line-derived EGFR multiplex cell-free DNA reference standard allows laboratories and assay developers to optimize, validate, and routinely monitor performance of polymerase chain reaction–based tests, next-generation sequencing, and other novel assays designed to detect EGFR mutations from cfDNA.
Confocal laser scanning microscope, 3/18
March 2018—Olympus announced the availability of the FV3000 confocal laser scanning microscope in two upright models designed for in vitro and in vivo experiments.
Thermo Fisher unveils line of NGS instruments, 3/18
March 2018—Thermo Fisher Scientific announced the Ion GeneStudio S5 Series, a line of benchtop next-generation sequencing instruments that provides flexibility and scalability enabled by five Ion S5 chips, including the new Ion 550 chip, on a single platform. Research applications include cancer, inherited disease, and microbial and infectious diseases.
FDA-cleared Access AMH immunoassay, 3/18
March 2018—Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman’s ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.
Genoptix to acquire Rosetta Genomics, 3/18
March 2018—Genoptix and Rosetta Genomics announced they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a total gross purchase price of $10 million.
Recombinant allergens, 3/18
March 2018—Meridian Life Science introduced its recombinant allergens for the development of serum-based IgE-mediated allergen diagnostic assays.
Updated CLSI Supplement M100, 3/18
March 2018—The Clinical and Laboratory Standards Institute published its annually updated antimicrobial susceptibility testing supplement, “M100: Performance Standards for Antimicrobial Susceptibility Testing, 28th ed.,” as well as its associated methodology standards, “M02: Performance Standards for Antimicrobial Disk Susceptibility Tests, 13th ed.” and “M07: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed.” M100 is available packaged with either M02 or M07 or the three documents are available packaged together.